October 16, 1991 |
Ruth Deadmon, a near mute, waits outside the office of Dr. Daniel Truong, desperately hoping her voice can be restored. Deadmon is typical of Truong's patients: She awoke one day with what she thought was laryngitis. It has lasted seven years. Deadmon's condition has become so severe she sometimes cannot eat. She no longer answers her phone.
July 29, 1997 |
Allergan Inc. signed an agreement to sell its line of Imidazyl/Herbe over-the-counter eye drops to international pharmaceutical company Recordati S.P.A. Financial terms were not disclosed. Allergan said the product line includes Imidazyl decongestant eye drops, Imidazyl Antihistamine eye drops for allergic and inflammatory states of the eye and conjunctivitis, and Herbe eye drops for cases of mild irritation.
May 10, 2002 |
Allergan Inc.'s suit to block rival Alcon Laboratories Inc. from selling a generic version of its Alphagan glaucoma treatment was dismissed by a federal judge. Allergan said it plans to file an expedited appeal. The suit concerns patents relating to a brimonidine tartrate solution. Alphagan accounted for about 15% of Irvine-based Allergan's sales in 2000 and 2001, according to filings with the Securities and Exchange Commission. The company reported $1.75 billion in sales last year.
December 14, 1999
Allergan Inc. said Monday that the U.S. Food and Drug Administration has approved the marketing of the company's Alocril solution for the treatment of itch associated with allergic conjunctivitis. Allergan expects to launch the product by March. "The approval of Alocril provides an important new option for the treatment of a common ocular disorder," said Dr. Lester J. Kaplan, who heads the Irvine eye care company's research and development.
January 19, 2005 |
Allergan Inc., the maker of Botox injections to smooth wrinkles, said it would consolidate its European research and development operations to save as much as $9 million a year. Operations at the plants to be closed will be moved to Britain, Ireland and the U.S., Irvine-based Allergan said. The closings, which also affect some sales operations, will cost the company about $50 million to $60 million through the second quarter of 2006. Shares of Allergan rose $1.24, or 1.6%, to $81.02 on the
April 26, 2000
The Irvine research and development arm of eye-care company Allergan Inc. reported a net loss of $17.2 million, or $5.24 a share, for the first quarter, compared with a loss of $10.8 million, or $3.30 a share, for last year's first three months. Quarterly revenue fell to $980,000 from $2.15 million.
June 29, 1999 |
Eye-care-products maker Allergan Inc. said it will pay up to $11 million to license a bacteria-fighting protein from biopharmaceuticals maker Xoma Ltd. for use in a family of eye-infection treatments. Xoma, which is based in Berkeley, said Irvine's Allergan will make a series of licensing payments as development and sales goals are reached. Allergan also will pay development costs for future products and royalties from sales of products containing the anti-bacterial protein, which Xoma will manufacture for Allergan.
February 11, 1990
In reference to the article in the Orange County Business section (Jan. 25) about Allergan Inc., I would like to clear up some misunderstandings. The headline, "Allergan, Reporting Loss, Will Close Irvine Plant" was misleading in that it may have implied the company was closing down its Irvine operations. We employ over 2,000 people at our international headquarters in Irvine, which includes office, research, development and manufacturing operations. The first paragraph indicated that as a result of a fourth-quarter loss, Allergan would shut down a manufacturing plant here.
January 24, 2006 |
Botox maker Allergan Inc. said it was extending its $3.2-billion offer to buy breast implant maker Inamed Corp. because it had yet to get antitrust clearance from regulators. The offer is now set to expire at 8 p.m. on Feb. 7; it had been set to expire today. Irvine-based Allergan and Santa Barbara-based Inamed said they were working with the Federal Trade Commission to complete the sale of Inamed's license for Reloxin, a botulism toxin product.